Success Metrics

Completion Rate
0%(0/1)
Active Trials
3(43%)
Terminated
1(14%)

Phase Distribution

Ph phase_2
3
43%
Ph phase_3
3
43%
Ph phase_1
1
14%

Phase Distribution

1

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

7

all time

Status Distribution
Active(5)
Terminated(1)
Other(1)

Detailed Status

Recruiting3
Not yet recruiting2
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
3
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 23 (42.9%)
Phase 33 (42.9%)

Trials by Status

not_yet_recruiting229%
recruiting343%
terminated114%
unknown114%

Recent Activity

3 active trials
Showing 5 of 7
recruitingphase_1

Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer

NCT07632365
not_yet_recruitingphase_2

Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.

NCT07469241
recruitingphase_3

Adaptive Immunotherapy for Nasopharyngeal Carcinoma

NCT07154069
not_yet_recruitingphase_3

Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma

NCT06957938
recruitingphase_2

GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma

NCT06455410
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07632365Phase 1

Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer

Recruiting
NCT07469241Phase 2

Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.

Not Yet Recruiting
NCT07154069Phase 3

Adaptive Immunotherapy for Nasopharyngeal Carcinoma

Recruiting
NCT06957938Phase 3

Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma

Not Yet Recruiting
NCT06455410Phase 2

GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma

Recruiting
NCT03745222Phase 3

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer

Terminated
NCT03588494Phase 2

Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer

Unknown

All 7 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
7